Zemplar paricalcitol: Phase IV data

The open-label, international Phase IV IMPACT-SHPT trial in 272 patients showed that a significantly greater proportion of patients receiving IV Zemplar achieved mean intact PTH levels of 150-300 pg/mL during weeks 21-28, the primary endpoint, vs. IV cinacalcet plus low-dose vitamin D (57.7% vs. 32.7%, p=0.016). A non-significantly greater proportion of patients receiving oral Zemplar achieved the endpoint vs. oral cinacalcet plus low-dose vitamin D (54.4% vs. 43.4%, p=0.26). Data were published in Nephrology Dialysis Transplantation. ...